European Pharmaceutical Review

OCTOBER 7, 2022

A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Leading companies in the oral solid dosage market are Catalent, Inc.,

Dosage 98

Dosage Pharmaceutical Companies Pharmaceutical Companies Compounding 98

European Pharmaceutical Review

AUGUST 15, 2023

billion by 2030, according to a report from Data Bridge Market Research. This represents a compound annual growth rate (CAGR) of close to 10 percent. According to the report buccal delivery is the “most feasible and preferred choice compared to oral dosage forms, particularly among elderly patients.” billion in 2023 to $7.13

Dosage 52

Dosage Compounding 52

European Pharmaceutical Review

FEBRUARY 3, 2023

The facility forms two new fully-automated production lines for liquid and freeze-dried drugs, including highly potent compounds and advanced therapies such as antibody drug conjugates (ADCs). The HPAPI market A 2022 market report showed that due to the small volumes required for dosage, small-scale providers are also gaining importance.

Dosage 98

Dosage Pharmaceutical Companies Pharmaceutical Companies Compounding 98

Pharmacy Times

JUNE 19, 2025

With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings. 2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025.

Compounding 65

Compounding Compounding Pharmacies FDA Immunization 65

PharmTech

JUNE 26, 2025

million) in non-dilutive funding through i-Nov, an innovation competition and flagship French government program that is part of the France 2030 initiative, operated by Bpifrance (1). Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs Paul L. Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs Paul L.

Dosage 59

Dosage Vaccines Compounding Labelling 59

PharmTech

JUNE 10, 2025

The global biopharma industry is expected to increase at a compound annual growth rate of 8.97% from 2025 to 2030; this growth is suspected to result from a demand for targeted therapies, new alliances, and increased innovation (1).

Dosage 52

Dosage Vaccines Compounding Immunization 52

ISPE

SEPTEMBER 11, 2023

Examples include platforms as small as autonomous units placed within a facility and mobile production trailers for compounding to platforms as large as a prefabricated, self-contained GMP facility. POD is suitable for a wide range of products, including oral solid dosage forms, mAbs, and cell therapy. AAPS PharmSciTech 23, no.

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Documentation 52